Global Neurology Academy: Recent Episodes
ReachMD
The Global Neurology Academy (GNA) Series offers certified education modules and video interviews from leading MS experts from across the globe as they address topics such as induction therapy in relapsing-remitting multiple sclerosis; No Evidence of Disease Activity (NEDA) concept; how different agents used in MS management may be utilized in induction therapy; appreciation of how reductions in end-organ damage impact patient quality-of-life; mechanisms of action of the classical as well as emergent agents; key issues associated with making the correct differential diagnosis of multiple sclerosis, in addition to how best to incorporate prognostic indicators into clinical decision-making; current and emergent novel oral agents in MS management; and diagnostic strategies and identifying predictors of outcome. For more information about GNA, visit www.globalneurologyacademy.org.
Host: Perry Shieh, MD, PhD
Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.
Host: Craig M. McDonald, MD
Guest: Crystal Proud, MD
Guest: Aravindhan Veerapandiyan, MD
There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies.
Host: Robert Shin, MD, FANA, FAAN
Guest: Enrique Alvarez, MD, PhD
Guest: Jiwon Oh, MD, PhD, FRCPC
The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.
Host: Robert Shin, MD, FANA, FAAN
Guest: Enrique Alvarez, MD, PhD
Guest: Jiwon Oh, MD, PhD, FRCPC
The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.
Host: Stephen Krieger, MD
Guest: Tirisham Gyang, MD
Guest: Augusto Miravalle, MD, FAAN
New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.
Host: Stephen Krieger, MD
Guest: Tirisham Gyang, MD
Guest: Augusto Miravalle, MD, FAAN
New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.
Host: Heidi M. Munger Clary, MD, MPH
Guest: Jay Salpekar, MD, FANPA
A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they raise awareness about the high prevalence of comorbid mental health disorders, particularly depression, among epilepsy patients. Together, they explore the bidirectional relationship between epilepsy and depression, emphasizing the importance of early detection and comprehensive treatment. They’ll also cover implantable therapies, specifically vagal nerve stimulation devices, as potential tools to manage both epilepsy and depression.
Host: Heidi M. Munger Clary, MD, MPH
Guest: Jay Salpekar, MD, FANPA
A crucial aspect of epilepsy care that often goes underappreciated is the intersection of epilepsy and depression. Join Drs. Munger Clary and Salpekar, leading experts in the field, as they raise awareness about the high prevalence of comorbid mental health disorders, particularly depression, among epilepsy patients. Together, they explore the bidirectional relationship between epilepsy and depression, emphasizing the importance of early detection and comprehensive treatment. They’ll also cover implantable therapies, specifically vagal nerve stimulation devices, as potential tools to manage both epilepsy and depression.
Host: Mike Sharma, MD, MSc, FRCPC
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Stuart Connolly, MD, FRCPC
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Greg Albers, MD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Greg Albers, MD
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Stuart Connolly, MD, FRCPC
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Greg Albers, MD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Natalie Kreitzer, MD, MS
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Rhonda Cadena, MD, FNCS, FCCM
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Greg Albers, MD
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: Manesh R. Patel, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Ashkan Shoamanesh, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Valeria Caso, MD, PhD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Natalie Kreitzer, MD, MS
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Rhonda Cadena, MD, FNCS, FCCM
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: W. Brian Gibler, MD, FACEP, FACC, FAHA
Host: Rhonda Cadena, MD, FNCS, FCCM
Host: Adrian R. Parry-Jones, FRCP, PhD
Host: Stuart Connolly, MD, FRCPC
Join experts and explore an exciting new frontier of care for patients on direct oral anticoagulants who present with an intracranial hemorrhage. Three factors can be used to optimize treatment: emerging data on anticoagulation reversal, artificial intelligence utilization, and evidence-based ABC care bundling. Learn how these developments transform clinical practice, deepen institutional expertise, and ultimately improve patient outcomes.
Host: Ashkan Shoamanesh, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Manesh R. Patel, MD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Valeria Caso, MD, PhD
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Mike Sharma, MD, MSc, FRCPC
This program addresses critical gaps in healthcare professionals' knowledge and practice related to the secondary prevention of a clot-related stroke in patients with an acute ischemic stroke or at high risk for TIA. By addressing these gaps and achieving the outlined learning objectives, participants will be better equipped to provide optimal patient care, ultimately improving outcomes in managing this critical medical condition.
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Richard S. Isaacson, MD
Guest: Pierre N. Tariot, MD
Guest: Gayatri Devi, MD, MS, FAAN, FACP
Alzheimer’s Disease (AD) has historically been a condition associated with more questions than answers. These questions are only increasing with the flurry of developmental activity in recent years, particularly the introduction of the first ever disease modifying therapies, as the clinical picture is dramatically changing each day. To help address rising challenges prompted by this shifting paradigm, this activity features real questions from practicing clinicians regarding the integration of and expert perspectives on amyloid-targeting therapies for the treatment of AD.
Note: This program was recorded prior to the January 31, 2024 decision to withdraw aducanumab from the market. Though amyloid targeting therapy is available, this particular agent can no longer be prescribed. For more information, see: https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Kevin Trice, MD
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Ana C. Krieger, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
Host: Diana Kimmel
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Logan Schneider, MD
Host: Diana Kimmel
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Lee Surkin, MD, FACC, FCCP, FASNC, FAASM
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Matthew Davis, MD
Host: Alcibiades J. Rodriguez, MD, FAASM
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Matthew Davis, MD
Host: Logan Schneider, MD
The goal of this program is to address the unmet clinical needs associated with enhancing the accuracy and timeliness of diagnosing Idiopathic Hypersomnia (IH), acknowledging the cardiovascular implications of IH, and developing a comprehensive treatment strategy. This curriculum incorporates compelling patient video vignettes that convey the perspective of individuals living with IH and the profound impact that it has on their lives. This program aims to not only educate healthcare professionals on the rapidly evolving field but also to bring about positive changes in clinical practice, ultimately leading to an enhanced quality of life for individuals affected by IH.
Host: Kevin Trice, MD
This program aims to provide healthcare professionals (HCPs) with a comprehensive, evidence-based curriculum in caring for individuals with Narcolepsy. This curriculum addresses unmet clinical needs, including improving the accuracy and timing of diagnosing Narcolepsy, understanding how Narcolepsy increases the risk of cardiovascular disease, and addressing how treating Narcolepsy can improve sleep, which is an important aspect of overall health. The main goal is to educate clinicians about the latest developments in this field in order to positively impact clinical practice and significantly improve the quality of life for individuals affected by Narcolepsy.
This program covers best practices in:
- Recognizing the symptoms of Narcolepsy, including the common ones and those that are less well-known
- Exploring the relationship between cardiovascular disease and Narcolepsy
- Addressing diagnosis and treatment of Narcolepsy in relation to the AHA Life Essential 8, which focuses on key aspects of a healthy lifestyle
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Mark S. Freedman, MSc, MD, FANA, FAAN, CSPQ, FRCPC
Host: Bianca Weinstock-Guttman, MD
This program examines the significant challenges encompassing the management of Multiple Sclerosis (MS), including the need for quick and effective screening tools to help clinicians increase early diagnosis and the initiation of therapy. While there is currently no cure for MS, the treatment landscape is rapidly changing, and this program provides a review of best practice guidelines and emerging treatment strategies, including the S1P drug treatment class. There are also inequities relating to the level of care white patients with MS receive compared to non-white patients with MS, especially African Americans and Hispanic-Latinx. This program educates clinicians on the racial and ethnic disparities that produce barriers for minorities concerning MS diagnosis and treatment and helps close the gap.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Host: Kevin Trice, MD
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Kevin Trice, MD
Host: Michael E. Yurcheshen, MD, FAASM
Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Christina Finch, MD
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Atul Malhotra, MD
Host: Neomi Shah, MD, MPH, MSc
This curriculum focuses on the recognition and management of excessive daytime sleepiness (EDS) in patients with treated obstructive sleep apnea (OSA). Evidence-based treatment strategies for OSA will be reviewed, including best practices for the use of novel pharmacotherapeutics in the management of persistent EDS caused by OSA.
Host: Elaine C. Wirrell, M.D.
Guest: Joseph E. Sullivan, MD
This Expert Exchange webcast is designed to enhance clinicians’ awareness of emerging pharmacotherapies that demonstrate promise in optimizing seizure burden in patients with Lennox-Gastaut and Dravet syndromes.
Host: Elaine C. Wirrell, M.D.
Guest: Joseph E. Sullivan, MD
This Expert Exchange webcast is designed to enhance clinicians’ awareness of emerging pharmacotherapies that demonstrate promise in optimizing seizure burden in patients with Lennox-Gastaut and Dravet syndromes.
Host: Jennifer Caudle, DO
Guest: John F. Brandsema, MD
Guest: Vamshi K. Rao, MD
Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Because LGMD is so variable, it can be hard to detect and there are no FDA-approved treatments currently. Advances in gene transfer therapy have been slow to emerge. However, helping clinicians detect LGMD and know the next best steps is critical to effective management of LGMD, along with identifying patients for clinical trials.
Host: Jennifer Caudle, DO
Guest: John F. Brandsema, MD
Guest: Vamshi K. Rao, MD
Limb-girdle dystrophy (LGMD) is a group of inherited neuromuscular diseases with at least 34 variants, all affecting muscles of the limb-girdle region. Because LGMD is so variable, it can be hard to detect and there are no FDA-approved treatments currently. Advances in gene transfer therapy have been slow to emerge. However, helping clinicians detect LGMD and know the next best steps is critical to effective management of LGMD, along with identifying patients for clinical trials.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Julie Parsons, MD
Guest: Craig Zaidman, MD
Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.
Host: Mary Katherine Cheeley, PharmD, BCPS, CLS, FNLA
Guest: Julie Parsons, MD
Guest: Craig Zaidman, MD
Duchenne Muscular Dystrophy, or DMD, is considered a rare disease, affecting 1 in 3,500 boy births. But to the patients afflicted-and to the families who love them-it is a painful, everyday experience. Current advances in gene transfer therapy are exciting. Helping clinicians interpret and utilize the outcomes of gene therapy clinical trials is critical to effective treatment and management of DMD, as is the coordination of multidisciplinary teams for the ongoing care of these patients.
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Host: Jeffrey L. Neul, MD, PhD
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Host: Alan K. Percy, MD
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Host: Alan K. Percy, MD
Guest: Jeffrey L. Neul, MD, PhD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Host: Jeffrey L. Neul, MD, PhD
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Guest: Alan K. Percy, MD
Rett Syndrome (RTT) is an X-linked dominant genetic disease estimated to affect one in every 10,000 to 15,000 live female births across all racial and ethnic groups. It is the second most common cause of mental disability in females. RTT is associated with a spectrum of subtle symptoms, many of which manifest during specific ages during a child's development. Delayed diagnosis of RTT is very common. The inability to differentiate the subtle signs of RTT impedes a proper diagnosis and delays medical interventions desperately needed for positive patient outcomes. Recognizing the subtle symptoms and deploying the multidisciplinary healthcare team earlier is vital in improving patient quality of life and decreasing psychosocial stress. The desired outcome of this educational initiative is to help the multidisciplinary team understand the circumstances that impede an early diagnosis, improve the ability to recognize and diagnose the subtle signs and symptoms of RTT earlier, impart best practices in deploying the multidisciplinary team, and raise the awareness of current and emerging therapeutics used to manage RTT.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This first activity focuses on the rise of amyloid-targeting DMT and the subsequent key features of ARIA that impact all specialties.
Host: James Galvin, MD, MPH, FANA
Guest: Gloria Chiang, MD
Guest: Christopher Carpenter, MD, MSC, FACEP, FAAEM, AGSF
Guest: Charles P. Vega, MD
Recently, Alzheimer’s Disease (AD) saw its first approvals for disease-modifying therapy (DMT). With amyloid-beta (Aβ) targeting DMT now a reality, the entire way this condition is viewed and managed is changing. In particular, amyloid-related imaging abnormalities (ARIA), the most common adverse effects seen in DMT trials, are unique to this agent class, raising new questions and considerations across multiple medical specialties. As there is limited formal guidance on how to recognize and mange ARIA, this activity series employs experts in the fields of neurology, radiology, emergency medicine, and primary care to provide insight into how their fields are evolving to accommodate ARIA and to outline individual roles and best practices across specialties. This six-part series features distinct programs designed to introduce ARIA, detail its recognition and management in specific clinical settings, and ultimately optimize collaborative care.
This first activity focuses on the rise of amyloid-targeting DMT and the subsequent key features of ARIA that impact all specialties.
Guest: Daniel Kremens, MD, JD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Daniel Kremens, MD, JD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Rajesh Pahwa, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Daniel Kremens, MD, JD
Guest: Rajesh Pahwa, MD
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Daniel Kremens, MD, JD
Guest: Rajesh Pahwa, MD
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Rajesh Pahwa, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Daniel Kremens, MD, JD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Daniel Kremens, MD, JD
Guest: Rajesh Pahwa, MD
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Guest: Daniel Kremens, MD, JD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Daniel Kremens, MD, JD
Guest: Rajesh Pahwa, MD
Guest: Stuart H. Isaacson, MD
Parkinson’s Disease Psychosis (PDP) is a chronic, severely debilitating, and progressive neurodegenerative illness. PDP was once believed to be primarily a motor dysfunction disease, but it is now known to be multifaceted, encompassing cognitive and neuropsychiatric complications. PDP, which may include visual phenomena, hallucinations, and delusions, has been reported in up to 60% of patients and causes a substantial burden to the patient and their care partners. Early identification and treatment intervention are critical to lessening the patient’s burden. The goal of this educational series is to convince clinicians that integrating routine screening for PDP for all patients with Parkinson’s earlier in their journey is the right thing to do, to uncover PDP symptoms sooner, and to select an approved treatment option for PDP to improve patient outcomes and quality of life.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Sanjay Kumar, PhD
Temporal lobe epilepsy (TLE) is the most common form of focal epilepsy. Due to recent research from Florida State University, we might have a better understanding of the potential link between a specific protein and increased vulnerability to neurodegeneration among patients with this disorder. Dr. Andrew Wilner is joined by Dr. Sanjay Kumar, Professor of Biomedical Sciences and Neuroscience at Florida State University, to discuss this new discovery.
Host: Jerome Lisk, MD
Guest: Mark Mintz, MD
Recent developments in artificial intelligence (AI) technology have shown to aid with neurological disease diagnosis, risk stratification, treatment response, and more. So what are the newest AI applications? And perhaps even more importantly, what’s to come in the future? To find out the answer to these and other key questions, Dr. Jerome Lisk speaks with Dr. Mark Mintz, Chief Medical Officer and Founder of NeurAbilities Healthcare, to discuss emerging AI tools in the field of neurology.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Zachary Marcum, PharmD, PhD
Hypertension affects nearly half of adults in the United States and is associated with cognitive decline and dementia. A wide variety of antihypertensive medications are prescribed to millions of people to control blood pressure and prevent vascular dementia. Could it be that certain medications are better than others in preventing brain injury from chronic hypertension? Dr. Andrew Wilner is joined by Dr. Zachary Marcum, Associate Professor in the School of Pharmacy-University of Washington, to discuss his recent study investigating the association between certain hypertension medications and reduced cognitive impairment.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Andrew Chan, MD
Increasing evidence indicates the involvement of B cells in the pathogenesis of multiple sclerosis (MS), but their exact role is unclear. Despite that uncertainty, B-cell depletion therapies have shown to ease symptoms, prevent relapses, and even slow the course of the disease. So how exactly do B-cell therapies work, and how do we know if they’re right for our patients? Joining Dr. Charles Turck to talk about the role of b-cell therapies for our MS patients is Dr. Andrew Chan.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
Guest: Daniel George, MSc, PhD
Although there’s still no cure for Alzheimer’s disease, we’ve made great strides in understanding the tragic disease that affects more than 50 million people worldwide. So what are the latest updates in treating and alleviating this disease? To learn more about what’s new in Alzheimer’s disease research, Dr. Jerome Lisk speaks with Dr. Peter Whitehouse and Dr. Daniel George, co-authors of American Dementia: Brain Health in an Unhealthy Society.
Host: Jerome Lisk, MD
Guest: Peter Whitehouse, MD, PhD
The FDA’s recent approval of aducanumab for the treatment of Alzheimer’s disease has been met with a controversial response. So what do we need to know about this new drug and its potential to treat this progressive neurological disorder? Dr. Jerome Lisk is joined by Dr. Peter Whitehouse from Case Western Reserve University to break down the approval of this new drug and what it could mean for patients.
Host: Hector O. Chapa, MD, FACOG
Guest: Ahmed Zayed Obeidat, MD, PhD
Unfortunately, not all of our patients with multiple sclerosis (MS) respond well to treatment. That’s why it’s critical to constantly assess their response to treatment and notice the signs that someone might be an efficacy-challenged patient. But what exactly are those signs, and how can you go about switching therapies? Joining Dr. Hector Chapa to share key strategies for managing efficacy-challenged patients with MS is Dr. Ahmed Obeidat.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Vikram V. Bhise, MD
Guest: Patty Bobryk, MHS, PT, MSCS, ATP
When it comes to managing multiple sclerosis (MS), it’s important to keep the patient at the center of care by learning about their unique goals as well as the sociodemographic and socioeconomic factors affecting them. So how can we learn more about our patients, and once we do, what evidence-based management strategies are available to us? Joining Dr. Charles Turck to share how we can tailor treatment plans for our patients with MS are Dr. Vikram Bhise and certified assistive technology practitioner Ms. Patty Bobryk.
Host: Andrew Wilner, MD, Author of "The Locum Life: A Physician's Guide to Locum Tenens"
Guest: Cheryl Carcel, MD, PhD
Although research suggests that women have a similar stroke risk as men, a new analysis has found that a very small percentage of participants in clinical trials investigating stroke treatments are female. So why are women underrepresented in these clinical trials, and what can be done to reverse this troubling trend? Joining Dr. Andrew Wilner to discuss strategies to improve the representation of women in stroke trials is Dr. Cheryl Carcel, neurologist and senior research fellow at the George Institute of Global Health.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Margaret Chisolm, MD
The Diagnostic and Statistical Manual of Mental Disorders (DSM) is the handbook traditionally used by healthcare professionals to guide the diagnosis of psychiatric conditions, but a number of psychiatrists advocate for the perspectives approach, which extends beyond the DSM model. So how exactly do these two models differ? And how might this newer approach impact our patients? Joining Dr. Charles Turck to answer those and other key questions on the perspectives approach to diagnosing and treating patients with mental illness is Dr. Margaret Chisolm, author of From Survive to Thrive: Living Your Best Life with Mental Illness.
Host: Clete A. Kushida, MD, PhD
Guest: Lois E. Krahn, MD
Tune in to hear about new treatments for patients with narcolepsy. Data were recently presented at the American College of Chest Physicians Annual Meeting, and Drs. Clete Kushida and Lois Krahn are breaking it down for you: they examine the evolving treatment landscape and dive into the latest research on currently available and emerging pharmacologic options including the expanding range of oxybate therapies. Join us and find out why it’s such an exciting time to be caring for patients with narcolepsy.
Host: Jerome Lisk, MD
Guest: Tissa Wijeratne MD PhD FRACP FRCP FAAN
Since the onset of the COVID-19 pandemic, researchers and clinicians alike have strived to address the mysteries surrounding the virus, including its long-term side effects on patients. So what we do need to know about the emerging syndrome pointing to COVID-19’s neurological and cognitive impacts? To find out, Dr. Jerome Lisk is joined by Dr. Tissa Wijeratne, the Director of the Department of Neurology and Stroke Services at the University of Melbourne, to talk about post-COVID-19 neurological syndrome.
Guest: Ann D. Bass, MD
Guest: Barry A. Singer, MD
Multiple sclerosis is a chronic inflammatory and neurodegenerative disease with a highly variable clinical course.1,2 Most patients who have relapsing-remitting multiple sclerosis (RRMS) will eventually transition to a secondary progressive course (SPMS).3 Patients with SPMS may live with significant impairment in physical and cognitive functions.4 Early identification of disease progression is important.2
Join Dr. Barry Singer from the MS Center for Innovations in Care at the Missouri Baptist Medical Center in St Louis, Missouri as well as Dr. Ann Bass from the Neurology Center of San Antonio in San Antonio, Texas as they share their real-world clinical perspectives on the management of patients with more progressed RMS, including those with aSPMS, and MAYZENT as a treatment option. Together, they will explore the following decision points:
- How to actively identify first signs of RMS progression
- A therapy for progressing RMS, including active SPMS
- What to consider when getting patients started on MAYZENT, a disease-modifying treatment
Host: Jerome Lisk, MD
Guest: Shivashankar Othy, DVM, PhD
Despite the high prevalence of multiple sclerosis (MS), there’s still a lot we don’t know about this disease. One such area of uncertainty is in regard to how MS causes the immune system to become dysfunctional, but this knowledge is key as it could help us develop new treatment options. And now, we might be one step closer to discovering those treatments thanks to a recent study exploring specific T cells, and joining Dr. Jerome Lisk to discuss that study is Dr. Shiva Othy, a Project Scientist in the Department of Physiology and Biophysics at the University of California Irvine School of Medicine.
Host: Louis Kuritzky, MD
Guest: Karl Doghramji, MD, FAASM, DFAPA
Guest: Julie Flygare, JD
Guest: Phyllis C. Zee, MD, PhD
Excessive sleepiness is a common, highly impactful problem not commonly reported and frequently misdiagnosed by physicians. While prevalence reports of narcolepsy vary, patients often do not seek medical advice for their symptoms or, if they do, they receive inaccurate diagnoses. Because of this, it’s possible that more than 1 in 2000 people are living with narcolepsy. It may even take 10 to 15 years to be diagnosed, during which time these patients are impaired. What signs and symptoms are both clinicians and patients missing?
Tune in to hear a patient, Julie Flygare, JD, recount her bizarre symptoms and receive clinical tips on how to improve your identification of overlooked sleep disorders and narcolepsy. Drs. Zee, Doghramji, and Kuritzky provide their clinical insight and expertise on this serious medical condition that continues to be grossly misdiagnosed, underdiagnosed, and undermanaged. By improving your ability to detect, accurately diagnose, and appropriately manage narcolepsy, you can improve the quality of life and health outcomes for your patients. Find out what subtle signs and red flags you need to be on the lookout for and what exciting therapies are now available for these patients.
Host: Clete A. Kushida, MD, PhD
Guest: Michael J. Thorpy, MD
While gaps in care remain, the future is bright for patients with narcolepsy. Data from cutting-edge clinical trials were recently presented at 2021 Virtual Sleep, the 35th Annual Meeting of the Associated Professional Sleep Societies, and Drs. Clete Kushida and Michael Thorpy are ready to break it down for you. Join them as they examine the main barriers to timely diagnosis and treatment and then dive into the latest research on currently available and emerging pharmacologic therapies. Tune in to stay up to date on the latest progress and research on the management of patients with narcolepsy.
Guest: Maheen Mausoof Adamson, PhD
Tune in to hear Dr. Maheen Mausoof Adamson, a Clinical Associate Professor of Neurosurgery at Stanford School of Medicine, discuss her study on mental health in women and how we can take a more targeted treatment approach.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Maheen Mausoof Adamson, PhD
Traumatic brain injury, or TBI, manifests differently in men and women. Here to explore these differences is Dr. Maheen Mausoof Adamson, a Clinical Associate Professor of Neurosurgery at Stanford School of Medicine, meets with Dr. Andrew Wilner to discuss traumatic brain injuries in female patients.
Guest: Caroline Hastings, MD
Guest: Raymond Y. Wang, MD
Niemann-Pick disease type C (NPC) is an ultra-rare, inherited, neurodegenerative disease with life-threatening complications. Due to its highly variable onset of neurological symptoms throughout one’s lifespan, recognizing and establishing diagnosis for NPC can be challenging for any clinician.
That’s why Drs. Caroline Hastings and Raymond Y. Wang join Dr. Jennifer Caudle to help address those challenges with a detailed look at this genetic condition, the factors underlying its variable onset and course, and strategies to improve recognition, cross-specialty communications, and time to diagnosis.
Copyright ©2021 Orphazyme A/S. All rights reserved.
Host: David Weisman, MD
Guest: Elizabeth Finger, MD
Patients with frontotemporal dementia, or FTD, suffer from shortfalls in social and emotional behavior. But emerging research might help guide us in treating this disorder. Dr. David Weisman meets with Dr. Elizabeth Finger, a clinical neurologist and an Associate Professor of Neurology at Western University in Canada, to discuss her latest research on FTD.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Paller, PhD
Lucid dreaming is complex and remains a mystery to many neurologists, but emerging research suggests we may be able to communicate with dreamers in REM sleep. Dr. Andrew Wilner is joined by Dr. Ken Paller, Northwestern University's Director of the Cognitive Neuroscience program and the training program in the Neuroscience of Human Cognition, to discuss his recent research on communicating with lucid dreamers.
Host: Hector O. Chapa, MD, FACOG
Guest: Colin Quinn, MD
Guest: Matthew Wicklund, MD
Dr. Colin Quinn and Dr. Matthew Wicklund discuss the genetic and pathophysiologic underpinnings of limb girdle muscular dystrophy, as well as the use of appropriate diagnostic tests for accurate identification of LGMD.
Host: Jennifer Caudle, DO
Guest: Crystal Proud, MD
Guest: Edward Clinton Smith, MD
Dr. Crystal Proud and Dr. Edward Smith discuss the relationship of DMD genetics and pathophysiology and explain the importance of early diagnosis of Duchenne Muscular Dystrophy and the challenges associated with making this diagnosis.
Host: Jerome Lisk, MD
Guest: Ilan Wittstein, MD
How do you mend a broken heart? Dr. Ilan Wittstein, the Director of the Advanced Heart Failure Fellowship and Assistant Professor of Medicine at Johns Hopkins School of Medicine, joins Dr. Jerome Lisk to discuss broken heart syndrome and some of its challenges.
Host: Jerome Lisk, MD
Guest: Jerrold Vitek, MD, PhD
Deep brain stimulation, or DBS, is an emerging surgical procedure that may help to manage movement disorders such as Parkinson’s disease. Dr. Jerrold Vitek joins Dr. Jerome Lisk to share what is to be expected when a patient undergoes this type of procedure.
Host: David Weisman, MD
Guest: Adil Javed, MD PhD
How can providers help mitigate the symptoms of a disease a debilitating as multiple sclerosis? Dr. David Weisman examines management strategies for patients with multiple sclerosis with is Dr. Adil Javed, a board-certified neurologist and an Associate Professor of Neurology at the University of Chicago.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Jennifer A. Frontera, MD
Although the impact of COVID-19 can be long-lasting, many have had similar effects, even if they aren’t diagnosed with the disease. Dr. Jennifer Frontera, a neurocritical care specialist and professor of neurology at the NYU Grossman School of Medicine, shares some insight on the neurological symptoms that patients with COVID-19 are facing.
Host: David Weisman, MD
Guest: Mijail D Serruya MD,PhD
Thousands of Americans live with the debilitating aftereffects of stroke, such as arm and communication problems. This makes technological developments like brain-computer interfaces absolutely critical for stroke survivors, but some questions are beginning to arise regarding the ethics of this technology. So in order for us to fully pursue this advancement, it’s important that we address those ethical concerns, as Dr. Mijail Serruya explains.
Host: Patricia K. Coyle, MD
Guest: Jiwon Oh, MD
Treatment goals for patients with multiple sclerosis continue to be refined as more and better disease-modifying drugs emerge from clinical trials and we accrue findings from real-world data. Nonetheless, the decision to match a patient with a particular drug agent has become more complex as we strive to achieve our treat-to-target goals and optimize patient outcomes.
Drs. Coyle and Oh discuss how clinicians can best approach the medical management of patients with multiple sclerosis, both in the short and long term. The goal is to apply best clinical evidence while personalizing a patient’s therapy, thus offering the patient as normal a life as possible.
Host: Andrew Wilner, MD, FACP, FAAN
Guest: Ken Tyler, MD
Further complicating the COVID-19 pandemic is the emergence of viral variants. Dr. Ken Tyler from the University of Colorado School of Medicine shares with us what we know so far about the COVID-19 variants that are quickly spreading around the world.
Host: Patricia K. Coyle, MD
Guest: Mitzi Joi Williams, MD
While we are witnessing an impressive expansion in the multiple sclerosis treatment landscape, we cannot lose sight of the fact that a critical component of care is the incorporation of best clinical evidence into the personalized management of each patient.
Join us as Drs. Coyle and Williams discuss how bringing shared decision-making into the management of multiple sclerosis can help us to not only achieve our treat-to-target goals, but also improve patient outcomes and satisfaction.
Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Drew Weissman, MD, PhD
Dr. Drew Weissman, Professor of Medicine at Penn Medicine joins Dr. Turck to discuss his new COVID-19 vaccine technology and how RNA and mRNA are being used to provoke an immune response in order to combat the COVID-19 pandemic.
Host: Jerome Lisk, MD
Guest: Anthony L. Fine, M.D
Recent advancements in the field of fetal neurology have equipped clinicians to detect neurological diseases before the child is even born. Dr. Jerome Lisk joins Dr. Anthony Fine, a pediatric neurologist and epileptologist at Mayo Clinic in Rochester, to discuss some of these advancements.
Host: Robert A. Hauser, MD, MBA, FAAN
Guest: Stuart H. Isaacson, MD
Please note: This activity is no longer available for continuing education credit.
This Expert Exchange activity is designed to make clinicians aware of the potential for emerging pharmacotherapies in treating patients with Parkinson’s disease.
You can access the Clinical Compendium for Novel Therapies to Manage OFF Episodes in Patients with Parkinson’s Disease by clicking the link here.
Host: Jennifer Caudle, DO
Guest: Amit Bar-Or, MD, FRCP, FAAN, FANA
Joining Dr. Jennifer Caudle to discuss the latest research furthering our understanding and treatment of multiple sclerosis is Dr. Amit Bar-Or, Chief of the Multiple Sclerosis Division and Director for the Center of Neuroinflammation and Neurotherapeutics at Penn Medicine. Could these recent findings finally help us solve some of the unanswered questions of multiple sclerosis?
Host: Jennifer Caudle, DO
Guest: Catherine Apicella, MPT, PYT-C, PRPC
Frustrating multiple sclerosis (MS) symptoms like urinary frequency and incontinence can be detrimental to a patient’s quality of life, but there are resources available to help. To explore the benefits of pelvic floor physical therapy for MS, Dr. Jennifer Caudle sits down with two special guests: physical therapist Catherine Apicella from CORE 3 Physical Therapy and her patient—and ReachMD’s very own employee—Crystal Gouldey.
In this interview, Lawrence Sherman and Dr. Ralf Gold discusses the study, "Immunologic Effects of Metformin and Pioglitazone Treatment on Metabolic Syndrome and Multiple Sclerosis," which was led by researchers, Laura Negrotto and Dr. Raul Carrea. They will also discuss the impact of the drugs on clinical biomarkers and MRI, as well as future research on immunologic effects tied to MS.
This interview is supported by an educational grant from Merck KGaA, Darmstadt, Germany.